Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics

Sidley represented Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, in its acquisition of Faeth Therapeutics Inc., a clinical-stage biotechnology company developing multi-node therapies targeting tumor metabolism and signaling.

Concurrent with the acquisition, Sidley also represented Sensei in its definitive agreement for the sale of Series B non-voting convertible preferred stock in a private placement expected to result in gross proceeds of approximately US$200 million.